Answers are grounded in this paper and cite their sources.
Tightly connected symptom networks have previously been linked to treatment resistance, but most findings come from small sample studies comparing single responder vs. non-responder cross-sectional networks. We aimed to estimate the association between baseline network connectivity and treatment response in a large sample and benchmark its prognostic value against baseline symptom severity and variance. N=40,518 patients receiving treatment for depression in routine care in England from 2015-2020 were analysed. Cross-sectional networks were constructed using the Patient Health Questionnaire-9 for responders and non-responders (N=20,259 each). To conduct parametric tests investigating the contribution of mean and variance to connectivity differences, networks were constructed for 160 independent subsamples of responders and non-responders (80 each, n=250 per sample). The baseline network of non-responders was more connected than responders (3.15 vs 2.70, S=0.44, P<.001), but effects were small, requiring n=750 per group to have 85% power. Parametric analyses of the 160 independent networks revealed baseline network connectivity, mean, and variance were correlated (r=0.20-0.58, all P<.001). Both mean (β=-1.79, SE=0.07, P<.001), and variance (β=-1.67, SE=0.09, P<.001) had larger effect sizes for predicting response than connectivity (β=-1.35, SE=0.12, P<.001). The association between connectivity and response disappeared when variance was accounted for (β=-0.28, SE=0.19, P=.14). We replicated these results in patients completing a longer duration of treatment (8-12 weeks, N=22,952) and using anxiety symptom networks (N=70,620). The association between baseline network connectivity and treatment response may be largely due to differences in baseline symptom variance. Future work should focus on intraindividual, not cross-sectional networks.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) studied this question.